Healthcare shares were generally higher in pre-market trade on Monday.
In healthcare stocks news, Inovio Pharmaceuticals ( INO ) Monday reported net loss attributable to common stockholders of $10 million, or $0.05 per share, for Q1 ended March 31, 2014 versus last year's net loss of $6.6 million, or $0.04 per share. The increase in loss came from an increase in non-cash stock-based compensation. The Capital IQ consensus was for a $0.04 loss per share.
The biotechnology company generated $2.4 million in revenues versus $1.5 million for the same period in 2013. The average estimate by five analysts, according to the Capital IQ consensus was for revenues of $1.4 million.
And, SciClone ( SCLN ) reported Q1 loss of $0.10 per share, which beat the analyst consensus for a $0.08 per share loss. Revenue of $26.6 million missed the Street view.
Finally, Flamel Technologies ( FLML ) said its Q1 adjusted net loss narrowed as sales topped estimates, with the company recognizing revenue from Bloxiverz for the first time.
Bloxiverz is the first of a line of products acquired from Eclat to receive U.S. Food and Drug Administration approval.
The adjusted net loss was $4.2 million, or $0.15 a share versus an adjusted net loss of $5.9 million or $0.23 a share in the first quarter of 2013, in line with analysts' estimates.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.